What is Pfizer’s Centers for Therapeutic Innovation?
Established in 2010, Pfizer’s Centers for Therapeutic Innovation (CTI) was founded on the notion that our current scientific and global health challenges are too complex for any one player in the healthcare ecosystem to solve alone. We believe that collaboration is critical to success. CTI collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients.
What is Pfizer’s Centers for Therapeutic Innovation?
Established in 2010, Pfizer’s Centers for Therapeutic Innovation (CTI) was founded on the notion that our current scientific and global health challenges are too complex for any one player in the healthcare ecosystem to solve alone. We believe that collaboration is critical to success. CTI collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients.
CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, Vaccines, and Internal Medicine with a strategic focus on the highly novel pan-therapeutic areas including RNA, Artificial Intelligence & Machine Learning, Biomolecular Condensates, Senescence, Repeat Expansion Disorders and DNA Damage Response.
Pfizer’s Centers for Therapeutic Innovation was born out of the need for a more dedicated collaboration vehicle with academia—recognizing that great science takes place anywhere in the world, both inside and outside the walls of Pfizer. Take a closer look at how this open innovation model supports collaboration between Pfizer scientists and academic investigators, helping to translate promising, early-stage scientific concepts into clinical candidates.
Recent Publications
Lewis Cantley, Ph.D.
Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Professor of Cancer Biology in Medicine
At CTI, there is a free exchange of information and the ability to bring in expertise from all parts of the company. You’re not just collaborating with one person in a company or even one division. We really shared it all in play – and it was quite unique. I can’t say there’s been any other collaboration I’ve been a part of with that level of accessibility and openness.
Clare Ozawa, Ph.D.
Managing Director, Versant Ventures
CTI’s efforts are synergistic with other models of advancing innovative science such as through venture capital. CTI uniquely progresses therapeutic discovery across numerous diseases by tapping into the breadth and depth of Pfizer’s significant drug discovery and development capabilities.
How it Works
CTI pursues breakthrough science at the earliest stages. We offer industry-leading drug development expertise combined with the infrastructure of a large biopharmaceutical company in an open, collaborative environment. Once we identify promising research, we work with academic investigators to navigate the challenges inherent in early translational science through hands-on support from subject matter experts across Pfizer and through our network in the broader life science community. Our most successful, enduring relationships rely on close collaboration between scientists. CTI assigns a scientific champion for each investigator and project, who understands and manages the project needs, and coordinates access to Pfizer’s global capabilities and scale to deliver optimal outcomes.
This is an exciting moment in R&D as the opportunity for scientific and medical advancement may never have been greater. CTI’s collaborative model deploys Pfizer R&D resources where breakthrough science is happening at the earliest stages, leveraging the full Pfizer enterprise to translate therapeutic hypotheses from academic collaborators into viable therapeutics. Building and expanding upon our visionary model for translational research, we have built a network of ongoing relationships with dozens of top-tier academic institutions globally.
In order to create equitable collaborations, CTI has established a model “Participation Agreement”, developed in conjunction with our early academic collaborators, under which joint drug discovery research programs with an academic institution sits. Projects are executed via Statements of Work that are governed by the Participation Agreement. If a Participation Agreement is not in place with your institution, CTI has several other contracting mechanisms to bring collaborative programs in.
Projects usually commence when a PI proposes a target that is ripe for mounting a drug discovery effort, and then progress collaboratively towards and into the clinic. To date, CTI has progressed 8 drug candidates to the clinic, of which 4 are in Phase II and 3 are in Phase I.
Areas of Interest
Inflammation & Immunology
Inflammation & Immunology
• Novel targets and mechanism to induce tolerance in autoimmunity, e.g. modulation of Mregs, Bregs, tolerogenic APCs
• Novel platforms to modulate undruggable targets, e.g. splicing modifiers, transcription factor targeting
• Novel mechanisms to target therapeutics to the gut
Not actively seeking partnering opportunities in:
• TNFα, IL-1ß targeting biologics
• B cell depleting biologics
• Corticosteroids
Internal Medicine
Internal Medicine
• Novel mechanisms and/or human genetic approaches to target heart failure with preserved ejection fraction (HFpEF), vascular dysfunction and lymphatic dysfunction
• New mechanisms and pathways for the treatment of diabetic nephropathy or chronic kidney disease, founded on evidence from human pathophysiology and/or genetics
• Mechanisms addressing cachexia associated with chronic disease and aging
Not actively seeking partnering opportunities in:
• Nutraceutical approaches to muscle growth and function
Oncology
Oncology
• Alteration of tumor evolution to prevent drug treatment resistance: Seeking targets involved in cancer cell mutagenesis, drivers of lineage plasticity, and the emergence of drug tolerant persister cells
• Transcription Factors: Novel oncogenic transcription factors and their complexes, as well as new mechanisms for their modulation
Not actively seeking partnering opportunities in:
• antibody-drug conjugates, rare tumor indications
Vaccines
Infectious Disease Vaccines
Infectious Disease Vaccines
• Protective cell mediated response to bacterial or viral infections
• Emerging virus threats
• Bacterial pathogens (e.g. Chlamydia trachomatis, Staphylococcus aureus
Not actively seeking partnering opportunities in:
• RNA vaccine strategies for Flu, COVID-19, RSV
Weining Lu, MD
Associate Professor of Medicine, Department of Medicine, Boston University Medical Center
CTI embodies the first-of-its-kind industry and academia collaboration model. Working with CTI, I’ve learned significantly more in terms of drug development. I have worked closely with CTI scientists, who have come to my office and helped map out next steps together from the very first step of proposal submission. This collaboration continues to be one of the best in my career.
Our Collaborators
Our Collaborators
Building and expanding on our visionary model for early translational research CTI has built an ever-evolving global network of ongoing relationships with dozens of academic medical centers and investigators. We work uniquely with academic investigators to navigate the challenges inherent in early translational science through hands-on support from industry experts across Pfizer. Our collaborators represent notable academic institutions where pioneering principal investigators (PIs) with promising potential drug programs are based. Most of our collaborating institutions are based near our CTI labs in Cambridge, MA, New York City, San Francisco and San Diego, however we also have successful collaborations with other institutions across the US and across the globe.
Daniel De Carvalho, Ph.D.
Senior Scientist, Princess Margaret Cancer Centre Associate Professor, Department of Medical Biophysics, University of Toronto Tier 2 Canada Research Chair in Neoplasms
Academic research and industry research are often disconnected, potentially delaying the translation of fundamental discoveries and novel biology into new medicines and therapies. CTI provides a very unique bridge that allows academic and industry researches to work together. This bridge is based on a clear collaboration roadmap, openness and aligned goals. It is an environment with the best of both worlds, where academic researchers bring new ideas and tools while Pfizer researchers bring their vast expertise in drug discovery. It is also a great opportunity for academic trainees to interact with industry in a very collaborative and hands-on experience. My collaboration with CTI is one of best I ever had.
Benedikt Kessler, Ph.D.
Professor of Biochemistry and Mass Spectrometry, University of Oxford
Our experience of working with CTI is unique in that our scientific champions at Pfizer are extremely dedicated and passionate about pursuing the feasibility and detailed biology of a potential drug target candidate. I have been very impressed by the professionalism, experimental power and resourcefulness that our CTI collaborators have shown in the course of our joint work, allowing to move forward at a fast pace. Also, there is a high level of trust in sharing novel ideas and scientific concepts between colleagues across this pharma - academia working group . This way of working together is fun - real drug co-discovery collaborative research.
Submit a Proposal
Please visit Partners | Pfizer for more ways to partner with Pfizer.
FAQs
CTI uniquely works with academic investigators to navigate the challenges inherent in early translational science through hands-on support from subject matter experts across Pfizer. We offer industry-leading drug development expertise combined with the infrastructure of a large biopharmaceutical company in an open, collaborative environment. Our most successful, enduring partnerships rely on close collaboration between scientists. For example:
- Our joint project teams create focused research plans based on agreed-upon scientific goals and deliverables, supported by complementary expertise of the investigator and Pfizer researchers throughout the length of the project.
- We offer the opportunity to work alongside our researchers in our labs in New York, California (San Francisco and San Diego) and Cambridge, MA to nurture joint decision-making, learning opportunities and relationship-building.
- CTI assigns a scientific champion for each investigator and project, who understands and manages the project needs, and coordinates access to Pfizer’s global resources, expertise and capabilities to deliver optimal outcomes. Our scientists actively engage from project conception to exit, ensuring hands-on support and transparent decision-making.
CTI takes a staged approach to collaboration to alleviate as much of the burden on the academic institution and investigator as possible. The first stage of the process is for a potential collaborator to discuss their potential idea with a Pfizer representative. Once reviewed investigators should submit a brief, two to three page non-confidential pre-proposal to CTI via our portal. Please note that investigators must use the approved Pre-proposal Template.
Pre-proposals pass through an initial triage phase to determine whether they are aligned with CTI’s areas of interest. Those that pass this triage are reviewed by a cross-functional committee represented by experts from across Pfizer’s Research Units and Partner Lines, such as Drug Safety, Chemistry, and BioMedicine Design. This committee will assess the feasibility of mounting a drug discovery program in the proposed research area, working with the relevant academic institution to determine which pre-proposals will progress to full proposal drafting.
Read more about what Pfizer's Chemistry and BioMedicine Design teams look for when evaluating pre-proposals.
Are you a Principal Investigator?
Contact your institution’s business or Tech Transfer Office (TTO) to find out if your institution is part of the CTI network. If so, they will be able to help you submit a pre-proposal for review. If your institution is not a part of the CTI network, please contact us at [email protected].
Are you in the business office / TTO of an academic institution?
In order to submit a proposal on the CTI website please click Register / Log In on the top right of the screen. Log in using your user ID and password.
If you have not logged in before, select Request an Account, complete the information required, and a member of our team will verify your details and provide access to the system. Once logged in, you will have access to the Pre-proposal Dashboard where you can create and monitor the status of submitted pre-proposals.
Please note that investigators must use the approved Pre-proposal Template that can be downloaded from the Pre-proposal Dashboard. Once the Investigator has finalized the application, click Create a New Pre-proposal. Fill in all the fields on the page, then attach the completed template at the top of the screen, and select “submit”. If you forgot your password, please select Reset password and an email will be sent to you.
Non-confidential pre-proposals must be submitted through your business / Tech Transfer Office (TTO) representative who will submit to the CTI portal on your behalf. If your TTO is unable to submit in this way, please ask them to contact us at [email protected]. If you are unable to reach your TTO, please contact us at [email protected]
Funding:
- CTI provides funding for joint research plans to support the activities being conducted in the PI’s lab. Research progression is tied to clear pre-defined go/no-go criteria at each stage, rather than a pre-defined length of time or a pre-defined amount of funding.
Intellectual Property:
- Each party retains ownership of the background IP it brings to the research program
- Each party grants to the other a non-exclusive, non-sublicensable license to use its background IP for the purposes of performing the research program
- Pfizer has the option to acquire an exclusive commercial license to the collaborator’s rights in IP generated during the research program and any background IP contributed to the research program
- For programs that successfully reach certain development milestones, Pfizer may exercise its option to take an exclusive license to any developed IP and background IP.
Confidentiality and Publications:
- During the research term, subject to customary carve-outs, neither Pfizer nor Participant may disclose the other party’s confidential information for the duration of, and for 5 years following the conclusion of, the research program. Confidential information includes a party’s background intellectual property, know-how, or other proprietary information or materials that have not been otherwise disclosed.
- Both parties have the right to publish findings from research programs. Prior to publishing, proposed disclosures must be reviewed by the other party to ensure that no confidential or patentable information is disclosed.
You do not need to have a master agreement in place to collaborate with CTI. However, please reach out to your institution’s business / Tech Transfer Office (TTO) to see if your institution has a CTI Participation Agreement.
Pre-proposals pass through an initial triage phase to determine whether they are aligned with CTI’s areas of interest. Those that pass this triage are reviewed by a cross-functional committee represented by experts from across Pfizer’s Research Units and Partner Lines, such as Drug Safety, Chemistry, and BioMedicine Design. This committee will assess the feasibility of mounting a drug discovery program in the proposed research area, working with the relevant academic institution to determine which pre-proposals will progress to confidential full proposal writing.
Full proposals are co-drafted by the academic investigator and a CTI research leader. These are detailed research plans outlining the goals, activities and ‘go’/ ‘no go’ criteria for the proposed project. If accepted, the full proposal progresses to the execution of a Statement of Work and the project begins.
As with all scientific endeavors, projects may terminate for many different reasons. Should Pfizer decide not to advance jointly developed molecules, the parties can discuss alternatives for those research programs, including the possibility of licensing the IP to third parties. Academic research rights are protected within this collaboration.
Yes, there are multiple opportunities to partner with Pfizer in different ways. To learn more please visit: https://www.pfizer.com/partners.
Jeffrey Bluestone, Ph.D.
A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes Center, University of California, San Francisco
Sometimes a project might not move forward – for any number of different reasons such as scientific or non-scientific concerns, but the project remains a promising idea and potentially viable, and the PI wishes to continue to explore, generating data that might be attractive to others, including Pfizer, down the road. So what makes CTI unique is that everyone wants to make sure that the investigator who was putting their heart and soul into the project is left with enabling tools to continue to advance the project. That is one of the main reasons I’ve continued to stay engaged with CTI over so many years, the relationship is really a partnership.